Cesium carbonate → (E)-1-(5-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-1-methyl-1H-1,2,4-triazol-3-yl)pyrrolidin-2-one

HRID 1055011ノート

反応式

HRID 1055011 の反応式
Br[C:2]1[N:6]=[C:5](/[CH:7]=[CH:8]/[C:9]2[N:19]=[C:12]3[C:13]([CH3:18])=[N:14][CH:15]=[C:16]([CH3:17])[N:11]3[N:10]=2)[N:4]([CH3:20])[N:3]=1.[NH:21]1[CH2:25][CH2:24][CH2:23][C:22]1=[O:26].C(=O)([O-])[O-].[Cs+].[Cs+].C1(P(C2C=CC=CC=2)C2C3OC4C(=CC=CC=4P(C4C=CC=CC=4)C4C=CC=CC=4)C(C)(C)C=3C=CC=2)C=CC=CC=1>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd].C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd].C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd].C1(P(C2C=CC=CC=2)C2C3OC4C(=CC=CC=4P(C4C=CC=CC=4)C4C=CC=CC=4)C(C)(C)C=3C=CC=2)C=CC=CC=1>[CH3:17][C:16]1[N:11]2[N:10]=[C:9](/[CH:8]=[CH:7]/[C:5]3[N:4]([CH3:20])[N:3]=[C:2]([N:21]4[CH2:25][CH2:24][CH2:23][C:22]4=[O:26])[N:6]=3)[N:19]=[C:12]2[C:13]([CH3:18])=[N:14][CH:15]=1

参加物

9

反応物 4

HCID 10796Cesium carbonateHCID 120252-PyrrolidoneHCID 6360441,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine)HCID 90025179(E)-2-(2-(3-bromo-1-methyl-1H-1,2,4-triazol-5-yl)vinyl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine

生成物 1

HCID 90026269(E)-1-(5-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-1-methyl-1H-1,2,4-triazol-3-yl)pyrrolidin-2-one収率 47.6%

試薬・触媒・溶媒 4

HCID 6360441,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine)触媒HCID 9811564Bis(dibenzylideneacetone)palladium触媒HCID 86718202tris(dibenzylideneacetone)dipalladium Pd2dba3触媒HCID 312751,4-Dioxane溶媒

反応条件

温度
140 °C

実験手順

An argon-purged mixture of (E)-2-(2-(3-bromo-1-methyl-1H-1,2,4-triazol-5-yl)vinyl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine (case 30922, Expl. 9a) p 31) (56 mg, 168 μmol, Eq: 1.00), pyrrolidin-2-one (28.6 mg, 25.7 μl, 336 μmol, Eq: 2), cesium carbonate (76.4 mg, 235 μmol, Eq: 1.4), tris(dibenzylideneacetone)-dipalladium(0)/Pd2(dba)3 (3.07 mg, 3.35 μmol, Eq: 0.02) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xant-phos) (3.88 mg, 6.7 μmol, Eq: 0.04) in dioxane (3 ml) was heated in a closed vessel for 1.5 hours at 140° C. under argon atmosphere. Up to 4 additional portions of Pd2(dba)3 and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xant-phos) are added and heating continued for another 1.5 hours until HPLC shows complete conversion of the Aryl bromide. The crude material was applied on silica gel and purified by flash chromatography over a 20 g silica gel column using ethyl acetate/methanol 5-10% as eluent affording 1-{5-[(E)-2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)-vinyl]-1-methyl-1H-[1,2,4]triazol-3-yl}-pyrrolidin-2-one (27 mg, 47.6%) as an off-white solid. MS: m/z=339.6 (M+H+), MP: 242.5° C.

後処理

  1. customAn argon-purged
  2. temperatureheating
  3. custompurified by flash chromatography over a 20 g silica gel column

出典と根拠

ORDレコード
ord-f363e09f8f5f40bca0fa8c5d9a66494f
出典データセット
uspto-grants-2016_07
特許番号
US09394311B2

反応ノート

読み込み中…